Avadel Pharmaceuticals reports increased demand for LUMRYZ, positive outlook for cash flow in 2025.

From GlobeNewswire: 2025-04-08 13:30:00

Avadel Pharmaceuticals presented at the 24th Annual Needham Virtual Healthcare Conference, reporting improved patient demand for LUMRYZ in Q1 2025. The Company’s Phase 3 pivotal trial for REVITALYZ is on track, and they initiated patent infringement lawsuits against Jazz Pharmaceuticals. Avadel expects positive cash flow in 2025 and has diversified its supply chain to mitigate potential U.S. tariff impacts. LUMRYZ, approved by the FDA in 2023, is the first once-at-bedtime treatment for narcolepsy. It has Orphan Drug Exclusivity and important safety information due to its controlled substance nature. Investors can access a webcast recording on their Investor Relations website for 90 days after the conference.



Read more at GlobeNewswire: Avadel Pharmaceuticals Provides Update at Needham Virtual